Showing results (1411-1420 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 12, 2013
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancerIsamu Okamoto, Keisuke Aoe, Terufumi Kato, et al.
Investigational New Drugs|January 25, 2013
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysisAlyssa Fischer, Shenhong Wu, Alan L Ho, et al.
Investigational New Drugs|February 15, 2013
Ipilimumab associated hepatitis: imaging and clinicopathologic findingsKyung Won Kim, Nikhil H Ramaiya, Katherine M Krajewski, et al.
Investigational New Drugs|January 10, 2013
Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancerPeter M Wilson, Melissa J Labonte, Shelby C Martin, et al.
Investigational New Drugs|January 10, 2013
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cellsAngel Mauricio Castro-Gamero, Kleiton Silva Borges, Daniel Antunes Moreno, et al.
Investigational New Drugs|December 25, 2012
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network studyNoelle K LoConte, Kyle D Holen, William R Schelman, et al.
Investigational New Drugs|January 1, 2013
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatmentMoshe Rogosnitzky, Milton J Finegold, Patricia J McLaughlin, et al.
Investigational New Drugs|February 1, 1990
Fluorinated anthracyclines: synthesis and biological activityK C Tonkin, R T Brownlee, F Zunino, et al.
Investigational New Drugs|February 1, 1990
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusionC J Fabian, R Molina, M Slavik, et al.
Investigational New Drugs|May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
Pageof 372